PixCell Medical Overview
PixCell Medical offers a true point-of-care solution for complete blood count (CBC) tests, providing lab-quality precision with a small, simple diagnostic device. Within six minutes, PixCell's HemoScreen hematology analyzer provides fast and accurate analysis for the five-part differential CBC test with just a single drop of blood. The HemoScreen provides insights on 20 standard blood count parameters and comprehensive abnormal cell flagging, improving accessibility to CBC testing and reducing diagnostic turnaround time. The FDA-cleared and CE-marked HemoScreen has been fully validated in various clinical and academic settings worldwide and shown to produce lab-accurate results with comprehensive flagging of abnormal cells. PixCell's patented Viscoelastic Focusing technology and AI-powered machine-vision technology enable earlier detection of complex diseases (e.g., leukemia, lymphoma, and other cancers and infections), allowing faster diagnosis and treatment and setting the stage for improved patient outcomes.
Cumulative Funding Raised Over Time ($)
$1.5MApr 2011
$2.5MFeb 2016
$4.5MOct 2013
Latest News
growth-positive
Clinical Evaluation Concludes PixCell Medical's HemoScreen is an Accurate and Easy-to-Use Point-of-Care Analyzer for Psychiatric Companion Diagnostics
PixCell Medicals HemoScreen has been found suitable for CBC companion diagnostics in point-of-care settings through a clinical evaluation conducted by researchers at the South London and Maudsley NHS Foundation Trust. The evaluation showed strong correlations between HemoScreens capillary and venous assays and the standard lab venous method. The device offers a portable, quick, and accurate alternative to current non-portable methods of clozapine monitoring, improving treatment enrollment and adherence. PixCell Medical is an innovator of rapid hematology testing solutions at the point-of-care, offering a 5-part differential Complete Blood Count (CBC) analyzer called HemoScreen.
Customers
growth-positive
New Age for Point-of-Care Diagnostics: PixCell Medical's HemoScreen Surpasses Leading Lab Hematology Analyzer Sysmex XN in Flagging of Abnormal WBC
A study published in eJHaem Journal of Hematology compared PixCell Medicals HemoScreen CBC analyzer with Sysmexs Sysmex XN CBC analyzer. The study showed that HemoScreen was more accurate and specific in detecting leukocyte abnormalities. It demonstrated better specificity (88% versus Sysmex XNs 72%) and was less prone to false flagging. This advantage in accuracy is attributed to HemoScreens novel machine learning-driven viscoelastic focusing technology. The study is the first to demonstrate a point-of-care CBC analyzers superiority over the lab-based flow cytometry analyzer. PixCell Medical is an innovator of rapid hematology testing solutions and has developed the FDA-cleared HemoScreen analyzer. The portable device provides lab-accurate readings of blood count parameters within five minutes.
PartnersCustomers
growth-positive
PixCell Medical Partners with Insight Medical to Distribute the Hematology Point-of-Care Analyzer HemoScreen™ in Papua New Guinea
PixCell Medical has announced a partnership with Insight Medical, a medical supply and service company based in Papua New Guinea. Insight Medical will serve as the exclusive distributor of PixCells HemoScreen™, a hematology analyzer designed for use at the point of care, across Papua New Guinea. This partnership will enhance healthcare quality in Papua New Guinea, particularly in rural communities where access to quality blood diagnostics is limited. HemoScreens lab-grade blood diagnostics capabilities will assist doctors in carrying out timely clinical interventions, especially for diseases like Malaria. PixCell Medical aims to expand to challenging and rural-centric regions, and this partnership aligns with their mission. PixCell Medicals HemoScreen™ is an FDA-cleared, CE-marked, and TGA-approved CBC analyzer that provides fast and accurate blood count parameters within five minutes.
Partners
growth-positive
New blood test device saves chemo patients time and energy
Israeli company PixCell Medical has developed the HemoScreen device, which enables cancer patients to perform pretreatment blood tests rapidly onsite or at home. The device delivers lab-accurate data from a single finger-prick of blood within five minutes, allowing patients to determine if their white blood cell count has recovered sufficiently for the next chemotherapy dose. PixCell has conducted successful clinical trials in Denmark, and is seeking regulatory approval for home-based CBC measurements in Europe. The company has received a grant to develop additional applications for the HemoScreen device and has won awards for its design. PixCell has seen significant demand for the device, with many hospitals ordering it to improve workflow.
Customers
growth-positive
PixCell Medical Awarded Grant by International Health-Tech Pilot Program
PixCell Medical has been awarded a grant by the International Health-Tech Pilot Program to develop and validate additional applications for its HemoScreen™ hematology analyzer. The program is an alliance between the Israel Innovation Authority and world-leading hospitals, aiming to increase the availability of new medical technologies. PixCell will cooperate with Charité Krankenhaus and the Berlin Institute of Health at Charité for the project. The HemoScreen™ is a 5-part CBC solution that provides lab-accurate diagnostic information from a single finger-prick of blood within five minutes. PixCell was one of four Israeli start-ups to receive funding out of over 70 companies that applied for the grant. The joint research initiative will be supervised by Prof. Dr. Lars Bullinger, Prof. Anne Flörcken, and Dr. Friedrich Wittenbecher at the Department of Hematology, Oncology and Cancer Immunology at Charité CVK.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $7.5M |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 6 |
| Investors | 2 |
Team Members
6
Employees: 51-200
Web & Social Links
| Website | www.pixcell-medical.com/ |
| Careers | Careers page |
Locations
HaYetsira Street 6, Yokne'am Illit, Israel
Photos & Videos
4 item(s)
PixCell Medical Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesDigital HealthcareDigital Medical DiagnosticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
Artificial IntelligenceComputer VisionTags (12)
blood-testmedical-technologiesmedical-devicesdiagnosticshematologyhealthcare-providershospitalshome-careartificial-intelligenceoncologydigital-healthcarepatientsGeographic Markets
United StatesAsiaNorth AmericaSouth AmericaUnited KingdomSwedenAustraliaNorthern EuropeGlobalDenmarkEuropeFinlandSwitzerlandPixCell Medical Financials
$7.5M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Acquired
Funding stage
6
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$1.5MApr 2011
$2.5MFeb 2016
$4.5MOct 2013
Private Equity Funding
B Round
Feb 2016
$1M
Undisclosed Investor(s)
A Round
Oct 2013
$2M
Undisclosed Investor(s), Orbotech
Seed
Apr 2011
$1.5M
Orbotech (Lead)
Non-Equity Funding
GrantEvent
Feb 2022
Undisclosed
International Health-Tech Pilot Program
GrantEvent
Mar 2018
$3M
European Commission
GrantEvent
Dec 2015
Undisclosed
Office of the Chief Scientist
Public Offering / Exit
MNAEvent
May 2021
Undisclosed
PixCell Medical Lifecycle
Cumulative Funding Raised Over Time
$1.5MApr 2011
$2.5MFeb 2016
$4.5MOct 2013
All Events
B Round
Feb 2016
$1M
Undisclosed Investor(s)
A Round
Oct 2013
$2M
Undisclosed Investor(s), Orbotech
Seed
Apr 2011
$1.5M
Orbotech (Lead)
GrantEvent
Feb 2022
Undisclosed
International Health-Tech Pilot Program
GrantEvent
Mar 2018
$3M
European Commission
GrantEvent
Dec 2015
Undisclosed
Office of the Chief Scientist
MNAEvent
May 2021
Undisclosed
PixCell Medical News
36 articles
growth-positive
Clinical Evaluation Concludes PixCell Medical's HemoScreen is an Accurate and Easy-to-Use Point-of-Care Analyzer for Psychiatric Companion Diagnostics
PixCell Medicals HemoScreen has been found suitable for CBC companion diagnostics in point-of-care settings through a clinical evaluation conducted by researchers at the South London and Maudsley NHS Foundation Trust. The evaluation showed strong correlations between HemoScreens capillary and venous assays and the standard lab venous method. The device offers a portable, quick, and accurate alternative to current non-portable methods of clozapine monitoring, improving treatment enrollment and adherence. PixCell Medical is an innovator of rapid hematology testing solutions at the point-of-care, offering a 5-part differential Complete Blood Count (CBC) analyzer called HemoScreen.
Customers
growth-positive
New Age for Point-of-Care Diagnostics: PixCell Medical's HemoScreen Surpasses Leading Lab Hematology Analyzer Sysmex XN in Flagging of Abnormal WBC
A study published in eJHaem Journal of Hematology compared PixCell Medicals HemoScreen CBC analyzer with Sysmexs Sysmex XN CBC analyzer. The study showed that HemoScreen was more accurate and specific in detecting leukocyte abnormalities. It demonstrated better specificity (88% versus Sysmex XNs 72%) and was less prone to false flagging. This advantage in accuracy is attributed to HemoScreens novel machine learning-driven viscoelastic focusing technology. The study is the first to demonstrate a point-of-care CBC analyzers superiority over the lab-based flow cytometry analyzer. PixCell Medical is an innovator of rapid hematology testing solutions and has developed the FDA-cleared HemoScreen analyzer. The portable device provides lab-accurate readings of blood count parameters within five minutes.
PartnersCustomers
growth-positive
PixCell Medical Partners with Insight Medical to Distribute the Hematology Point-of-Care Analyzer HemoScreen™ in Papua New Guinea
PixCell Medical has announced a partnership with Insight Medical, a medical supply and service company based in Papua New Guinea. Insight Medical will serve as the exclusive distributor of PixCells HemoScreen™, a hematology analyzer designed for use at the point of care, across Papua New Guinea. This partnership will enhance healthcare quality in Papua New Guinea, particularly in rural communities where access to quality blood diagnostics is limited. HemoScreens lab-grade blood diagnostics capabilities will assist doctors in carrying out timely clinical interventions, especially for diseases like Malaria. PixCell Medical aims to expand to challenging and rural-centric regions, and this partnership aligns with their mission. PixCell Medicals HemoScreen™ is an FDA-cleared, CE-marked, and TGA-approved CBC analyzer that provides fast and accurate blood count parameters within five minutes.
Partners
growth-positive
New blood test device saves chemo patients time and energy
Israeli company PixCell Medical has developed the HemoScreen device, which enables cancer patients to perform pretreatment blood tests rapidly onsite or at home. The device delivers lab-accurate data from a single finger-prick of blood within five minutes, allowing patients to determine if their white blood cell count has recovered sufficiently for the next chemotherapy dose. PixCell has conducted successful clinical trials in Denmark, and is seeking regulatory approval for home-based CBC measurements in Europe. The company has received a grant to develop additional applications for the HemoScreen device and has won awards for its design. PixCell has seen significant demand for the device, with many hospitals ordering it to improve workflow.
Customers
growth-positive
PixCell Medical Awarded Grant by International Health-Tech Pilot Program
PixCell Medical has been awarded a grant by the International Health-Tech Pilot Program to develop and validate additional applications for its HemoScreen™ hematology analyzer. The program is an alliance between the Israel Innovation Authority and world-leading hospitals, aiming to increase the availability of new medical technologies. PixCell will cooperate with Charité Krankenhaus and the Berlin Institute of Health at Charité for the project. The HemoScreen™ is a 5-part CBC solution that provides lab-accurate diagnostic information from a single finger-prick of blood within five minutes. PixCell was one of four Israeli start-ups to receive funding out of over 70 companies that applied for the grant. The joint research initiative will be supervised by Prof. Dr. Lars Bullinger, Prof. Anne Flörcken, and Dr. Friedrich Wittenbecher at the Department of Hematology, Oncology and Cancer Immunology at Charité CVK.
Partners
growth-positive
Israel's PixCell Medical Wins 2021 MedTech Visionaries Award
PixCell Medical has been presented with the 2021 MedTech Visionaries Awards for Best Medical Device and Best MedTech Visionary in the Field of Medical Devices for Real-Time Blood Testing. The companys HemoScreen, a portable and reliable instrument for real-time blood testing, has been recognized for its innovation. PixCell has developed imaging flow cytometry, which reduces the need for blood samples to be tested in a laboratory. The HemoScreen is FDA-cleared and CE-marked for point-of-care use and delivers lab-accurate results within five minutes. PixCell has received investment from Soulbrain, a semiconductor firm based in South Korea.
InvestmentPartners
growth-positive
PixCell Medical, Gamidor Diagnostics Ink Deal to Distribute Point-of-Care Hematology Analyzer
PixCell Medical has signed an exclusive distribution agreement with Gamidor Diagnostics to distribute its hematology analyzer, HemoScreen, in Israel. The agreement is expected to have a positive impact on the growth of PixCell Medical. In May, PixCell was acquired by South Korean semiconductor firm Soulbrain Holdings, which also invested over $40 million in the company.
Partners
growth-positive
PixCell Medical Announces Acquisition by Soulbrain Holdings
Soulbrain Holdings has acquired all controlling shares of PixCell Medical and has become the majority shareholder. The acquisition aligns with Soulbrains strategic transition into the healthcare and in-vitro diagnostics space. PixCell Medicals flagship product, HemoScreen™, is a point-of-care blood testing platform that provides quick and accurate diagnostic results. The acquisition by Soulbrain will help accelerate PixCells global expansion and commercialization of the HemoScreen.
Acquisition
growth-positive
PixCell Medical Partners with Axonlab to Distribute Point-of-Care Hematological Analyzer HemoScreen™ Across Europe
PixCell Medical has announced an exclusive distribution agreement with Axonlab to distribute its hematology analyzer, HemoScreen, in key European geographies. Axonlab will have exclusive distribution rights in Switzerland, Austria, the Netherlands, and the Czech Republic. The collaboration aims to enhance a clinicians diagnostic and decision-making capabilities by providing innovative diagnostic systems. HemoScreen is an AI-driven diagnostic tool that delivers lab-quality diagnostic results in significantly less time compared to traditional lab analyzers. It eliminates the need for routine maintenance and calibration and can be operated at the point of care. The partnership with Axonlab will increase the accessibility of the CBC blood test within the markets it serves.
Partners
growth-positive
RURAL Cohort Study to Utilize PixCell Medical's HemoScreen™ Hematology Analyzer for Research Initiative
PixCell Medicals portable hematology analyzer, HemoScreen, has been selected by the Risk Underlying Rural Areas Longitudinal Study (RURAL) for a six-year research study. The study aims to understand health concerns specific to rural communities in the southeastern United States. PixCells HemoScreen will be used to gather hematological data and provide insights into risk and resilience factors in rural communities. The portable and reliable nature of the HemoScreen makes it suitable for use in remote locations. PixCell Medical provides the first truly portable point-of-care blood diagnostic solution, delivering accurate readings of 20 standard blood count parameters within six minutes.
Partners
growth-positive
Aidian appointed sole distributor of PixCell Medical's HemoScreen in Nordic/Baltic Countries
PixCell Medical has announced a partnership with Aidian, a Finland-based in-vitro diagnostics company. Aidian will serve as the sole distributor of PixCells HemoScreen in Finland, Norway, Denmark, Latvia, and Estonia. The HemoScreen is a hematology analyzer designed for use at the point of care, providing rapid and accurate test results. The partnership aims to offer cost-effective and smart solutions for primary care. PixCell Medicals CEO highlights the importance of accessible diagnostic technology in combating global health threats. Aidian is a leading IVD company offering high-quality diagnostic solutions.
Partners
growth-positive
Israeli blood diagnostic solution hits Sweden
Israeli MedTech startup PixCell Medical has formed a strategic partnership with Nordic diagnostic distributor Triolab to expand its blood-based diagnostic device into Scandinavia. Triolab will be the sole provider of PixCells AI diagnostic solution in Sweden, with potential to expand into the rest of Scandinavia and the Baltics. PixCells HemoScreen diagnostic device delivers lab-like diagnostic results within six minutes at the point-of-care, without the need for qualified personnel. The partnership aims to bring rapid and reliable hematological test results to support physicians in clinical decision making. PixCell Medical recently received approval from the Australian government and launched its blood diagnostic device nationwide.
Partners
growth-positive
In-office blood test results in six minutes
PixCell Medical, an Israeli startup, has been recognized for its innovative HemoScreen system that delivers lab-equivalent results rapidly at the point of care. The system uses viscoelastic focusing technology to analyze a single drop of blood and provide results in just six minutes. PixCell Medicals HemoScreen competes with two other Israeli startups in the blood testing space. The company has received FDA clearance and has clients in Europe, Sweden, and Australia. The technology has become even more important during the COVID-19 pandemic for managing patients disease progression. PixCell Medicals CEO, Dr. Avishay Bransky, explains that the system can differentiate between different types and subtypes of cells and detect abnormal cells, making it more advanced than other analyzers.
CustomersPartners
growth-positive
PM360 2020 Innovative Company PixCell Medical
PixCell Medicals HemoScreen, an FDA-cleared diagnostic platform, delivers lab-quality blood count results within minutes. The platform utilizes Viscoelastic Focusing technology and AI-powered machine vision. It has been successfully deployed in various countries and proven effective in reducing turnaround time for blood count results in emergency settings. The HemoScreen has also been used in managing and monitoring COVID-19 patients. PixCell has provided 50 HemoScreen devices to the New South Wales Ministry of Health for use in small labs and remote communities. The platform is expected to launch in the United States in 2021.
CustomersPartners
growth-positive
Israel's PixCell to deploy blood test analyzers in Australia's New South Wales
PixCell Medical, an Israeli maker of point-of-care diagnostic devices, will be deploying its blood test analyzers in small labs and large emergency departments without onsite labs in New South Wales (NSW), Australia. The company will be working in collaboration with NSW Health Pathology to deploy PixCells HemoScreen hematology analyzers. HemoScreen is a low-cost portable hematology analyzer that can perform a complete blood count at the point of care. The collaboration includes the installation of a large number of devices in various healthcare settings. PixCell has previously worked with NSW Health Pathology to evaluate the HemoScreen device.
Partners
growth-positive
New Peer-Reviewed Study Demonstrates Ability of HemoScreen For Rapid Evaluation of Acute Leukemia Patients
PixCell Medical announced the results of a study demonstrating that their HemoScreen point-of-care hematology analyzer is suitable for evaluating and managing patients receiving chemotherapy treatment for hematological cancers. The study showed that the HemoScreen provides rapid and reliable test results for various blood parameters and can potentially eliminate unnecessary hospital visits. The HemoScreen is the only FDA-cleared hematology analyzer intended for use at the point-of-care and combines flow cytometry with digital imaging. PixCell Medical provides portable and fast blood diagnostic solutions using their patented Viscoelastic Focusing technology and AI-powered machine vision.
Customers
growth-positive
Israeli PixCell Medical scores Australia Gov. approval for blood diagnostic device at point-of-care
Israeli MedTech company PixCell Medical receives approval from the Australian government for its HemoScreen diagnostics device as a COVID-19 remote care solution. The company has formed commercial partnerships with Australian distributors and the Australian government is deploying the device to monitor COVID-19 patients remotely. PixCells HemoScreen uses advanced computer vision technology to rapidly analyze and differentiate cells within a blood sample, providing insights on 20 CBC parameters and early detection capabilities for various diseases. The device is designed to be simple to use and provides lab-accurate results within 6 minutes. PixCell Medical was founded in 2008 and has FDA and CE approval.
CustomersPartners
growth-positive
PixCell Medical Bolsters its Leadership, Adding Dr. David Stein as New Chairman of the Board
PixCell Medical has appointed Dr. David Stein as its new Chairman of the Board. Dr. Stein will focus on accelerating the commercial success and positive clinical impact of the HemoScreen platform. He will also work on scaling commercialization, operations, strategic planning, key partnerships, and regional expansion. Dr. Stein previously served as the Global Head of Strategy and President of Molecular Diagnostics for Siemens Healthineers. PixCell Medicals HemoScreen platform is an FDA-cleared hematology analyzer for point-of-care use. It delivers a full 5-part differential CBC with comprehensive abnormal cell flagging within six minutes.
Management Changes
growth-positive
Avishay Bransky, Ph.D., CEO and Co-founder of PixCell - Interview Series - Unite.AI
PixCell Medical, a medical technology company, has developed the HemoScreen hematology analyzer based on their patented Viscoelastic Focusing (VEF) technique. The HemoScreen simplifies blood testing and provides lab-quality results for a complete blood count (CBC) test within 6 minutes. It can detect diseases such as lymphoma, leukemia, and severe inflammation by identifying abnormal cells. PixCell Medical is also working on early sepsis diagnosis by adding specific biomarkers to the CBC test. The HemoScreen utilizes artificial intelligence (AI) and machine vision to rapidly analyze blood samples and classify different cell types. Decentralized diagnostic testing is important for early diagnosis of cancer and infectious diseases, as it allows for immediate testing and results, eliminating the need for centralized labs and reducing waiting times. PixCell Medical aims to provide accessible and accurate diagnostic solutions.
CustomersPartners
growth-positive
FDA clears diagnostic device using flow and imaging cytometry
PixCell Medical has developed an FDA-cleared platform for Point-Of-Care use that delivers lab-quality full five-part differential Complete Blood Count (CBC) results. The platform, called HemoScreen, provides accurate readings of 20 standard blood count parameters within six minutes using just one drop of blood. It requires no maintenance or calibration and can enable early detection of serious health issues. The device gained FDA clearance in November 2018. The CEO of PixCell Medical believes that this technology can make testing more accessible and improve healthcare services, potentially helping to manage future outbreaks more efficiently.
Customers
growth-positive
Home-Based Tests for Cancer Patients
The article discusses the use of point-of-care testing (POCT) as a safer way to monitor cancer patients during the COVID-19 pandemic. Zealand University Hospitals Department of Clinical Oncology has been using POCT devices to enable diagnosis and treatment of cancer patients, as hospital-acquired infections are a great concern for immunocompromised patients. The article emphasizes the need for easy, reliable at-home testing options for cancer patients, such as the complete blood count (CBC) test. The standard approach of centralized or hospital-based testing is challenging during a pandemic, and home-based care settings are becoming necessary. Implementing widespread POCT can make healthcare systems more efficient, drive the transition to home-based cancer care, and enhance patients wellbeing. The article was published on July 8, 2020.
Customers
growth-positive
The role of home-based blood diagnostics in future cancer care
The article discusses the need for home-based cancer care options, especially during the COVID-19 pandemic. Cancer patients, who are often immunosuppressed, face increased infection risks when visiting hospitals for treatment. The article highlights the importance of home-based diagnostics, such as accurate complete blood count (CBC) tests, to enable patients to receive treatment at home. The shift towards home-based care can optimize healthcare resources and improve patient experience. It is suggested that hospitals should focus on empowering patients and improving care delivery models to make hospitals more efficient and allow patients to receive care in the optimal environment for their recovery.
CustomersExpand
growth-positive
Are we about to see a new dawn for point-of-care testing?
The article discusses the potential approval of a Medicare rebate for point-of-care testing in Australia, specifically for monitoring diagnosed diabetes. The Medical Services Advisory Committee has supported the approach, and a decision is pending. Point-of-care testing has been hindered by skepticism, resistance from major pathology companies, and the lack of a Medicare rebate. The article highlights the benefits of point-of-care testing, such as shorter waiting times for crucial pathology results in rural areas and improved patient outcomes. The Australasian Association for Clinical Biochemistry and Laboratory Medicine supports the introduction of point-of-care testing, and the RACGP calls for its accessibility in general practice. The article also mentions the upcoming launch of a new Roche PCR test for influenza A, B, and the SARS-CoV-2 virus, which could be useful for GPs. The potential for point-of-care testing in other areas, such as sexually transmissible infections and hematology analysis, is also discussed.
Customers
growth-positive
How a Portable Israeli Blood Test Device Could Spur At-Home Chemo Treatments
PixCell Medical, an Israeli innovator of rapid point-of-care diagnostic systems, is collaborating with Interreg Germany-Denmarks Changing Cancer Care initiative to enable home-based testing of blood values for oncology treatment. The companys HemoScreen hematology analyzer, which provides rapid and accurate results, allows patients to perform the necessary blood tests at home, reducing the need for hospital visits. PixCells technology uses disposable cartridges and combines flow and imaging cytometry. The goal of the collaboration is to make at-home oncology treatment feasible and improve patient care. The company aims to expand the accessibility of lab-grade blood testing and enable early detection of health issues.
CustomersPartners
growth-positive
Why Decentralized Diagnostics Are Needed for Pandemic Management - Healthcare Business Today
The article discusses the importance of decentralized diagnostic testing, specifically in the context of managing the COVID-19 pandemic. It highlights the current challenges faced by healthcare systems in conducting diagnostic tests, particularly the complete blood count (CBC) test. The article emphasizes the need for affordable and effective point-of-care solutions to improve the situation. It also mentions the shortages of testing reagents and the potential benefits of rapid point-of-care CBC testing. The article is written by Dr. Avishay Bransky, CEO and co-founder of PixCell, a company specializing in microfluidics and diagnostic technologies. The impact on the company is growth-positive, as the article highlights the need for innovative diagnostic technologies, which PixCell specializes in.
CustomersPartners
growth-positive
https://www.jpost.com/health-science/hillels-tech-corner-bringing-blood-diagnostics-home-629528
The article discusses PixCell Medical, an Israeli company that offers a point-of-care solution for blood tests. The companys HemoScreen hematology analyzer provides fast and accurate analysis for the complete blood count (CBC) test, eliminating the need for multiple vials of blood and reducing waiting time for results. PixCell Medical has received $20 million in funding and its technology has been FDA-cleared for point-of-care use. The article highlights the importance of early detection in healthcare and how PixCells technology enables faster diagnosis and treatment, potentially improving patient outcomes. The companys accessible and easy-to-use diagnostic technology can be used in various care settings and is being tested for potential use in homes. Overall, the article has a positive impact on PixCell Medicals growth in the healthcare industry.
CustomersPartners
http://www.clpmag.com/2020/05/zealand-university-hospital-pixcell-medical-cooperate-advance-shift-home-care-cancer-patients/
growth-positive
Zealand University Hospital and PixCell Medical Cooperate to Advance Shift to Home Care for Cancer Patients
PixCell Medical has announced a collaboration with Interreg Germany-Denmarks Changing Cancer Care (CCC) initiative to assess the ability of PixCells HemoScreen hematology analyzer to enable home-based testing of blood values for cancer patients. The goal is to limit immunocompromised patients exposure to contagion in a hospital. The study will include three phases, with the final phase assessing the feasibility of using HemoScreen for CBC monitoring from home. HemoScreen is a CE-marked and FDA-cleared point-of-care diagnostic system that provides rapid and accurate results for blood testing. The collaboration aims to save time and costs for patients, clinicians, and healthcare systems.
Customers
growth-positive
PixCell's Viscoelastic Focusing Technology Shifts the Paradigm in Hematology Point of Care Accessibility
PixCell Medical Technologies has developed a portable cartridge-driven platform called HemoScreen™, which utilizes Viscoelastic Focusing Technology to provide rapid and accurate diagnostic information for complete blood counts. The technology, covered by numerous patents, offers a simpler and more reliable solution compared to existing methods. PixCell is a privately held Israeli company and its HemoScreen™ product is already CE marked and FDA cleared.
CustomersPartners
growth-positive
Rapid testing of red blood cell parameters in primary care patients using HemoScreen™ point of care instrument - BMC Primary Care
A study has found that PixCell Medicals HemoScreen instrument could be used in primary care to speed up the diagnosis of anemia. The instrument uses single sample cuvettes and image analysis of full blood count, including red and white blood cells, hemoglobin, and platelets. The study compared the HemoScreen and the Sysmex XN instrument results of 100 primary care patient samples, focusing on the total white blood cells, red blood cell parameters and platelets. The study concluded that the HemoScreen instrument could provide rapid and accurate test results for evaluation of the red blood cell parameters in primary care.
CustomersExpand
Rapid testing of red blood cells, white blood cells and platelets in intensive care patients using the HemoScreen™ point-of-care analyzer
growth-positive
Israeli blood analysis co PixCell wins €2.5m EU grant
Israeli blood analysis startup PixCell has been awarded a €2.5 million grant by the European Commission to accelerate the commercialization of its product, the HemoScreen. The funding will be used to further test the product in different clinical settings, demonstrate its clinical and economic benefits, and support production scaling. PixCells HemoScreen is a portable blood analyzer that can perform a complete blood count within 5 minutes, allowing physicians to diagnose and treat patients during a single visit. The technology is based on an innovative Lab-On-a-Cartridge concept and has been validated in clinical studies. PixCell is also developing additional assays based on the same technology. The article was published on March 15, 2018.
Investment
growth-positive
PixCell Medical Awarded 2.5 Million Euros Grant by the European Commission to Support Commercialization of its Disruptive Blood Testing Technology
PixCell has been awarded €2.5 million by the European commission to accelerate the commercialization of its product, the HemoScreen. The funding will be used to further test the product in different clinical settings, demonstrate its benefits, and support production scaling. The HemoScreen is a portable blood analyzer that performs a Complete Blood Count test within 5 minutes. It has been validated in 3 clinical studies in the US and is expected to be FDA cleared in 2018. PixCell is also developing additional assays based on the same technology. The companys website is http://www.pixcell-medical.com.
InvestmentExpand
The HemoScreen, a novel haematology analyser for the point of care
growth-positive
Cell based diagnostics co PixCell raises $2m
PixCell Medical Technologies has raised $2 million in funding following the completion of CE mark registration for its HemoScreen Complete Blood Count analyzer. The funds will be used to establish PixCells European presence and expand its clinical efforts to introduce the HemoScreen technology to the market. The HemoScreen CBC analyzer brings lab-quality diagnostics to various healthcare settings, requiring only a minute blood sample and zero maintenance. PixCells goal is to make lab restricted tests more accessible, easy to use, and affordable. The company plans to start a multi-center pilot study in Europe and Israel to evaluate the safety and performance of the HemoScreen system.
InvestmentExpand
N/A
PixCell Medical raised $2 Million Following CE approval its CBC Analyzer - Israel Electronics News
The article discusses the data collection practices of Techtime, a company that collects personal data for business purposes such as user experience enhancement and digital marketing. The company collects personal data through various forms on its website and uses Mailchimp for email collection and marketing materials. Techtime also uses Google Analytics for monitoring user behavior. The article emphasizes that all data collection and processing are done in accordance with GDPR requirements. Techtime shares data with various cloud platforms and third-party providers for website operation. The company ensures the protection of data through encryption, web application firewall, and regular security scans. In the event of a data breach, Techtime has procedures in place to assess and remedy the breach, as well as notify affected users. The article highlights that Techtime does not receive data from third parties for marketing campaigns.
CustomersPartners
PixCell Medical Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 68 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
PixCell Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 514145622 |
| Crunchbase | pixcell-medical |
| Phone | +97249593516 |
| Creator | Tamar Weiss |
| Creator email | tamar.e.weiss@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-02-13T00:00:00.000Z |
| Created | 2014-06-25T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Acquired by Soulbrain Holdings on May, 2021 |